Bicoll

MedChem Partners is a medicinal chemistry CRO founded in 2006 by Tsvetelina Lazarova and Steven Riesinger. The company is focused on using the extensive experience in early stage company formation and drug discovery to effectively advance small molecule candidates for clients by working closely with the client’s biology and/or chemistry resources. Our experts have extensive experience in moving projects from inception through discovery and into development up to IND enabling toxicology.

At MedChem Partners, we are experts at using synthetic and medicinal chemistry to develop small molecule therapeutics. Unlike large one-stop shops that spread their attention over a variety of tasks, we focus on what we know best. Our expertise is in formulating and implementing a plan to find and optimize small molecules which interact with novel or known biological targets. Whether you already have potential molecules in mind, or have just discovered a novel target, we can develop a plan to find and optimize compounds with therapeutic potential. Since drug discovery is a multidisciplinary endeavor, we have foraged close contacts with a variety of other service providers to augment our expertise in certain areas. Since each company is focused on what it does best, this approach allows us to tap into the best talent in each area. Through out network we have access to in vitro and in vivo testing, in vitro and in vivo pharmacokinetics, computer modeling and in silico prediction, formulation, scale-up and manufacturing, toxicology and regulatory filing, x-ray crystallography, intellectual property and patenting, and consultants in clinical, regulatory, manufacturing, pharmacology, and toxicology.

VENENUM Biodesign is focused on discovering and advancing innovative new medicines for significant unmet medical needs in key therapeutic areas, including; cancer, inflammation, infectious diseases, metabolic diseases, and women’s health. Our most advanced programs are targeting Clostridium difficile infection (CDI) and Type 2 Diabetes (T2D).

Our business model allows us to focus on the creation of high value, innovative small molecule programs against well-validated targets, as well as new targets identified from our own research and to work with partners for clinical and commercial development to bring our products to patients.

Our mission is to improve patients’ lives through the discovery of therapeutic compounds against our novel biological targets. Many of our targets involve novel protein-protein or protein-DNA interactions. Others are more conventional target classes e.g., GPCRs and enzymes. Our goal is to advance our discoveries to medicine through partnership with pharmaceutical companies.

We utilize state-of-the-art assay development and ultra-high throughput screening (UHTS) against our proprietary 6 million ECLiPS compound collection in conjunction with protein engineering and structural biology, medicinal chemistry, and in vivo models.

Vitas M Chemical (trademark Vitas-M Laboratory) has a good reputation as a supplier of small molecule organic compounds for research and development in pharmaceutical and agrochemical industry. We are on the market since 1998.

Our compounds are suitable for biological screening, lead optimization, fragment based drug discovery (FBDD), computer aided drug design (CADD), virtual docking, combinatorial chemistry and for other types of investigations in the field of Medicinal Chemistry and Molecular Biology. We carry stock of more than 1 400 000 compounds which is available for downloading from our web site.

All substances are available for searching and ordering in our web based search engine. Just visit our web site.

If you are in medicinal chemistry area take a look at collection of Fragments (chemical substances passed through "Rule of 3"​ and other special filters) for Fragments Based Drug Discovery (Allium Project).
If you are looking for special libraries of compounds for your research, we offer diversity and targeted libraries. They are calculated using modern computational algorithms, which allows to optimize efficiency and reduce potential complications of drug discovery process.

All compounds can be delivered in any format including mg, micromole, dry powder, DMSO solution, dry film.

Contact: irina@vitasmlab.biz

Absorption Systems, a Pharmaron company, is a full-service nonclinical CRO developing innovative services and solutions for the pharmaceutical, biotech, medical device and regenerative medicine industry. Our services include research and testing for small molecules, large molecules, biologics, medical device and cell and gene therapy products. The company's mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated outcomes when they occur. The company's facilities are strategically located in Philadelphia, San Diego, and Boston, servicing hundreds of customers throughout the world. Our focus is to maintain accuracy, timelines, and reliability at every stage of development. For more information on the company's comprehensive contract services and applied research programs, please visit absorption.com.

Eurofins Advinus is your trusted partner for specialized discovery, preclinical and early clinical services. Our facility has 30 years of GLP experience in conducting regulatory studies in compliance with global regulations for supporting clinical trials and registration of substances and products globally.

We have over a decade of drug discovery experience for novel, first-in-class targets as well as fast follow on targets and have produced multiple assets that are in preclinical and clinical development. Our discovery services include comprehensive offerings from Medicinal Chemistry, to in vitro Biology, ADMET and Pharmacology.

We offer end-to-end services for a complete IND/IMPD package that includes Safety Assessment/Toxicology and Drug Metabolism and Pharmacokinetic (DMPK) studies along with Chemistry, Manufacturing and Controls (CMC) services.

DMPK services include full spectrum of in vitro screening services, assay development and validation with customized assays and PK studies. We also provide bioanalytical assay development and validation services in accordance with USFDA and EMA guidelines for both Novel Chemical Entities (NCEs), as well as Novel Biological Entities (NBEs) and Biosimilars.

We have successfully submitted enabled 80+ IND packages for submission to regulatory agencies across the world – including USFDA, MHA and EMA. We offer full range of toxicology services to support NDA filing. We have completed 65+ carcinogenicity studies.